Bayer--new menopause drug in third Phase 3 clinical trial

Bayer’s elinzanetant is a non-hormonal drug that is in clinical development to treat vasomotor symptoms of menopause, such as hot flashes. The drug has shown positive results in two late-stage studies, and Bayer plans to seek regulatory approval for it after the third Phase 3 trial. The latest trial showed that elinzanetant reduces the frequency of hot flashes and improves sleep in menopausal women with moderate-to-severe symptoms. It also shows longer-term safety results.

Huge market when it hits the market. Pricing? No idea, but it says $500+ per month, which is a bit high, IMO. People will pay, no question.

2 Likes

Do you have a link?

DB2

First search result:

https://www.bayer.com/en/us/news-stories/elinzanetant